NCT05197322 - NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

December 31, 2028

Conditions

Adenocarcinoma of the Colon

Interventions

DRUG

Pembrolizumab

Dose: 200mg by IV infusion on Day 1 of each treatment cycle

Trial Locations (5)

NOT_YET_RECRUITING

Beatson West of Scotland Cancer Centre, Glasgow

RECRUITING

St James University Hospital (SJUH), Leeds

RECRUITING

University College Hospital, London

RECRUITING

Christie Hospital NHS Trust, Wilmslow Road,, Manchester

RECRUITING

Southampton General Hospital, Southampton